Seminars in Oncology
Volume 29, Issue 4 , Pages 389-399, August 2002

Adjuvant therapy for patients with high-risk malignant melanoma☆

San Diego Cancer Research Institute, and San Diego Melanoma Research Program, Vista, CA.

Abstract 

The role of adjuvant therapy in the treatment of patients with high-risk malignant melanoma remains an area of intense investigation. The initial enthusiasm for high-dose interferon has been tempered by the results of more recent studies that allow for conflicting interpretations. Vaccine therapy trials have failed to clearly demonstrate a survival benefit, although several trials are currently ongoing. Recent studies of the role of chemotherapy suggest there may be combinations that have a survival benefit which deserve further study. This article will address patient selection and staging workup, and review options for treatment. Semin Oncol 29:389-399. Copyright 2002, Elsevier Science (USA). All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Address reprint requests to Edward F. McClay, MD, Melanoma Research Center of San Diego, 910 Sycamore Aue, Suite 102, Vista, CA 92083.

PII: S0093-7754(02)50269-4

doi:10.1053/sonc.2002.34118

Seminars in Oncology
Volume 29, Issue 4 , Pages 389-399, August 2002

Article Tools

* Image Usage & Resolution